NT-0796 free base · Synonyms: NT 0796 · NT0796
NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor.
For research use only. Not for human or veterinary use.
Research area
Neurological Disease
Purity >98%
Stock Inquire
NT-0796 structure
CAS No.: 2272917-13-0
Pack sizes & pricing
| Size | Price | SKU | Stock | |
|---|---|---|---|---|
| 10 mg | USD 565.00 | BP-02258-10mg | In stock | Get quote |
| 25 mg | USD 1,085.00 | BP-02258-25mg | In stock | Get quote |
| 50 mg | USD 1,685.00 | BP-02258-50mg | In stock | Get quote |
| 100 mg | USD 2,084.00 | BP-02258-100mg | In stock | Get quote |
| 200 mg | Inquire | BP-02258-200mg | In stock | Inquire |
| 1 g | Inquire | BP-02258-1g | In stock | Inquire |
Description
NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor with an IC50 of 0.32 nM in PBMC assay.
Biological activity
NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor with an IC50 of 0.32 nM in PBMC assay. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 has the potential for neuroinflammatory diseases research.
Identifiers
- SMILES
-
O=C(O[C@H](CC1=NC=CC=N1)C(OC(C)C)=O)NC2=C3C(CCC3)=CC4=C2CCC4 - InChIKey
-
UMUQEMHROZVOTF-LJQANCHMSA-N
Specifications
- MW (average)
- 409.4782
- Formula
- C23H27N3O4
- CAS No.
- 2272917-13-0
- Physical state
- Solid
- Color
- White to off-white
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Solubility
Soluble in DMSO
- In vitro
- DMSO : 100 mg/mL
Documents
References
[1]. David Harrison, et al. Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders. J Med Chem. 2023 Oct 24.
[2]. Thornton P, et al. Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796. J Pharmacol Exp Ther. 2024 Feb 15;388(3):813-826.
[3]. Smolak P, et al. Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. J Pharmacol Exp Ther. 2024 Feb 15;388(3):798-812.
[4]. Doedens JR, et al. The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1. Biochem Pharmacol. 2024 Sep;227:116455.